Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesolv versus Rhinocort Aqua 64 in grass pollen-induced allergic rhinitis/rhinoconjunctivitis
2018-001324-19Phase 3Completed
- Sponsor
- Marinomed Biotech
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of budesolv and budesonide in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Marinomed Biotech. Primary endpoint: Total nasal symptom score. Started Jun 2018; status: completed.
02
Drugs
budesolvbudesonide
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2018-001324-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001324-19.